Navigation Links
100% Identification of Defective Blister Packs by Sepha's VisionsScan According to New Whitepaper
Date:3/4/2013

John Haran commented “Dr. Dixon’s study and findings demonstrate the VisionScan’s ability to offer a technologically advanced, non-destructive alternative for the integrity testing of blister packs, whilst delivering quality improvements and cost savings during production for global pharmaceutical manufacturers.”

Sepha serves the needs of the global pharmaceutical blister packing and leak testing markets and is doing business with many of the world’s top pharmaceutical manufacturers including Boots, Bayer, Novartis and GSK. It designs and builds machines at its factory base in Dundonald, Northern Ireland, and exports them to over 60 countries worldwide. For more information visit the Sepha website.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10483992.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. PathoGenetix Names Ann Merrifield as Chief Executive Officer and Prepares to Launch Unique Bacterial Identification Technology
2. AMRESCO Offers New Prism Protein Marker With Vibrant Colors For Easy Band Identification
3. Biodetection 2012 Conference Brings Together Leading Organizations from Around the World to Address Challenges & Technology Advances in Detection and Identification of Biological Threats in Washington, DC from June 28-29, 2012
4. Packaging Machinery Manufacturer, Sepha Ltd.Reports Record Year for Sales of its Visionscan Leak Detection Machine and its Pharmaceutical Deblistering Equipment
5. Small peptide ameliorates autoimmune skin blistering disease in mice
6. Up to the Challenge: Careers in Science in the Midst of Drastic Change, According to Wysebridge Patent Bar Review
7. 2013 Cold & Flu Statistics According to the Center for Disease Control & Prevention
8. Biotechnology guaranteed US$ 100 K to average Brazilian corn growers in four years, according to ABRASEM
9. BulletinHealthcare a TOP 10 “Most Innovative Company” of 2012 According to Pharma Marketing Publication PM360
10. Rigaku Publishes Application Note for Low Concentration Sulfur in Petroleum-based Fuels by WDXRF According to ASTM D2622-10
11. Rigaku Publishes New Application for Cement Analysis by the Pressed Powder Method on the ZSX Primus III+ According to ASTM C114-11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Robert Harman, ... Veterinary Medicine company, is proud to announce the relaunch of ... launching with a new series called “ What are Stem ... give an honest and straightforward foundation in the basics of ... educated decision on the right type of treatment when considering ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, ... report to their offering. ... photonic integration traces its roots in the latter ... photonic integration went unexplored and unfulfilled for several ...
(Date:7/10/2014)... microscopic polymer light resonators that expand in the ... Photonics Laboratory have developed new optical sensors with ... sensors are ideal for detecting trace gas concentrations ... nature, and immunity to electromagnetic interference. , Although ... the MIT team conceived an extremely sensitive, compact ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Swell new sensors 2
... 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China ... develops, manufactures, and markets specialty pharmaceutical products in ... completed Phase I clinical trials of its novel ... to be the most widely prescribed class of ...
... SAN DIEGO, Sept. 22 Marshall Edwards, Inc. (Nasdaq: ... development of novel anti-cancer therapeutics, announced today that Daniel P. ... update on Marshall Edwards and its novel oncology programs at ... beginning at 4:30 p.m. EDT from the New York Palace ...
... Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to... -- HOERSHOLM, Denmark and SAN DIEGO, Sept. ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 2China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 4Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 2Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 3Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 4Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 5Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 6Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 7Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 8Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 9Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 10
(Date:7/11/2014)... let nerve cells send out electrical signals, Johns Hopkins ... that may offer a new way to protect crops ... way. , Their findingthat naturally occurring insect toxins ... a closely related onesuggests that insecticides can be designed ... bees. A summary of the research, led by Frank ...
(Date:7/10/2014)... BEDFORD, Mass. , June 30, 2014  Aware, ... of biometrics software and services, previously announced on June ... a special cash dividend of $1.75 per share, or ... record date of July 10, 2014 and a payment ... notified by NASDAQ that it had set an ex-dividend ...
(Date:7/10/2014)... According to the new market research report, ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile Devices, ... and Geography - Global Trends & Forecasts to 2014 ... Market is projected to cross $14.35 Billion by 2020, ... to 2020. Browse more than 78 market ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... Scientists have found that a large proportion of infants ... disease. The disease is the most prevalent acute wheezing ... admission to hospital in the first year of life in ... admitted to hospital for bronchiolitis - needing oxygen and help ...
... from small rings of naturally occurring plant DNA can ... embryonic plants where they are expressed, duplicated as plant ... -- a long-term goal for those interested in improving ... issue of PLoS-Genetics, a team of academic and commercial ...
... Research Hospital have identified the cell that gives rise to ... growth and development. The finding suggests for the first time ... induce fully developed neurons to multiply and coax the injured ... work appears in the Oct. 19 issue of the journal ...
Cached Biology News:Scientists find predisposition to bronchiolitis in some babies 2Transgenics transformed 2Transgenics transformed 3St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory 2St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory 3
... The Cetac Ultrasonic Nebulizers are available in two ... difference between these two models is that the ... to create a drier aerosol for improved detection ... detection limits for a range of elements by ...
...
... A-type ribonucleases Product Description: ,QIAGEN RNase Inhibitor ... binds noncovalently and inactivates a variety of ... It does not interfere with RNase T1, ... RNase Inhibitor inhibits greater than 90% of ...
...
Biology Products: